HOTH - Hoth Therapeutics shares surge 56% on encouraging HT-002 data in COVID-19

Hoth Therapeutics (HOTH) soars 56% premarket after announcing new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a novel therapeutic targeted for the treatment of COVID-19. The lead HT-002 peptide candidate was shown to inhibit 50% of the cytopathic effect ((CPE)) of the SARS-CoV-2 virus at 61.7 µM (the EC50).Further, no cytotoxicity was demonstrated at concentrations of up to 200 µM of the peptide, supporting that this lead peptide has the potential to be a promising novel therapeutic for the treatment of COVID-19. Hoth plans to pursue further preclinical animal studies to support the therapeutic potential and investigate route of administration.

For further details see:

Hoth Therapeutics shares surge 56% on encouraging HT-002 data in COVID-19